SLC5A2 and chronic kidney disease: In particular, KDIGO advises using an SGLT2 inhibitor (Class I, Level A evidence) for all CKD patients with eGFR ≥ 20 mL/min/1.73 m2 who additionally exhibit HF or severe proteinuria (urine albumin-to-creatinine ratio ≥ 200 mg/g).